- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
CUDC-101 Provides Encouraging Results in Phase 1 Head and Neck Cancer
The drug targets multiple proteins that are overexpressed in head and neck cancer, the study published in Clinical Cancer Research says.
Head and neck cancer is among the few solid tumors whose incidence is increasing in the United States. and outcomes have been slow to improve. Results of a phase 1 trial of the drug CUDC-101 with radiation and chemotherapy were reported by the University of Colorado Cancer Center and 6 other US cancer centers in the journal Clinical Cancer Research.
CUDC-101, currently being developed by Curis, Inc, works by inhibiting two growth factors and an enzyme that effects DNA expression—EGFR, Her2 and HDAC—all of which are overexpressed in many cancers, including the target of this trial: the common type of especially aggressive head and neck cancer that is not caused by the human papilloma virus (HPV-) but rather by tobacco or alcohol.
Link to the complete report in ScienceDaily:
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
